Compass Therapeutics (NASDAQ:CMPX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Compass Therapeutics (NASDAQ:CMPX) released its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), FiscalAI reports.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX traded up $0.16 during mid-day trading on Friday, reaching $2.15. 3,825,555 shares of the company traded hands, compared to its average volume of 2,660,902. The company’s 50 day moving average price is $2.09 and its 200-day moving average price is $3.86. The firm has a market cap of $387.19 million, a PE ratio of -5.37 and a beta of 0.92. Compass Therapeutics has a 52 week low of $1.61 and a 52 week high of $6.88.

Analysts Set New Price Targets

CMPX has been the subject of a number of research reports. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a research report on Monday, June 1st. Citizens Jmp restated a “market outperform” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Tuesday, April 28th. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a report on Monday, April 27th. LADENBURG THALM/SH SH began coverage on shares of Compass Therapeutics in a research note on Wednesday, July 1st. They set a “buy” rating and a $5.00 price target on the stock. Finally, Wall Street Zen downgraded shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Compass Therapeutics has an average rating of “Moderate Buy” and an average price target of $11.77.

Key Compass Therapeutics News

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target on Compass Therapeutics from $4 to $6 and upgraded its outlook to “overweight,” implying substantial potential upside from recent trading levels. Benzinga article
• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $24 price target, signaling significant long-term upside if the company’s development programs progress successfully. The firm also modestly improved its FY2028 EPS forecast to a loss of $0.56 per share from a loss of $0.58.
• Neutral Sentiment: Analyst opinion is highly divided: Wall Street Zen reportedly downgraded Compass Therapeutics to “Strong Sell,” contrasting sharply with the Buy and Overweight ratings from HC Wainwright and Piper Sandler. Compass Therapeutics rating article
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for Q3 2026 to a loss of $0.15 from $0.11, Q4 2026 to a loss of $0.17 from $0.12, and full-year 2026 to a loss of $0.55 from $0.45. Its FY2027 forecast also declined slightly to a loss of $0.56 from $0.55.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the period. Creative Planning bought a new stake in Compass Therapeutics during the 2nd quarter valued at approximately $30,000. Strs Ohio purchased a new position in Compass Therapeutics in the 1st quarter worth approximately $34,000. CIBC Bancorp USA Inc. bought a new position in Compass Therapeutics in the 3rd quarter worth approximately $37,000. Finally, Virtu Financial LLC purchased a new stake in Compass Therapeutics during the 3rd quarter valued at approximately $44,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.